CD274 and non-small cell lung carcinoma: Follow-up of the NSCLC patients at a median of 4.3 months showed that the PD-L1 index increased significantly from 7.71 ± 2.90 at baseline to 9.72 ± 3.75 at follow-up (p-value = 0.0135; Figure 4).